Clinical research of infliximab in patients with severe refractory rheumatoid arthritis
XIE Xi
CHEN Jin-wei
GAO Jie-sheng
LI Fen
TIAN Jing
DU Jin-feng
WANG Jing
MAO Ni
Abstract：Objective:To evaluate 8-week effects and adverse reactions of infliximab in patients with severe refractory rheumatoid arthritis (RA). Methods:Ten patients with severe refractory RA were treated with infliximab (weeks 0, 2 and 6), and clinical, laboratory and psychological indices were recorded 1, 4, and 8 weeks after treatment. Results:The clinical, laboratory indices and DAS28 score observed in all of the patients were significantly improved (P<0.05), and no obvious adverse reactions were observed. Conclusion:Infliximab can quickly relieve the symptoms and the activated conditions of severe refractory RA within few weeks.
Keywords：rheumatoid arthritisefficacyinfliximab
Publication Date：2010-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 304-307 )